Analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to report earnings per share (EPS) of $2.89 for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Jazz Pharmaceuticals PLC’s earnings, with the lowest EPS estimate coming in at $2.78 and the highest estimate coming in at $3.00. Jazz Pharmaceuticals PLC posted earnings of $2.57 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 12.5%. The company is expected to issue its next quarterly earnings results on Tuesday, November 14th.

According to Zacks, analysts expect that Jazz Pharmaceuticals PLC will report full year earnings of $10.89 per share for the current year, with EPS estimates ranging from $10.74 to $11.05. For the next fiscal year, analysts anticipate that the company will report earnings of $12.98 per share, with EPS estimates ranging from $11.81 to $14.77. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Jazz Pharmaceuticals PLC.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The firm had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. During the same quarter last year, the business earned $2.67 earnings per share. The business’s revenue was up 3.5% compared to the same quarter last year.

Several brokerages have recently weighed in on JAZZ. Sanford C. Bernstein set a $176.00 target price on Jazz Pharmaceuticals PLC and gave the stock a “market perform” rating in a research report on Monday, May 22nd. Leerink Swann set a $179.00 target price on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Thursday, April 27th. Vetr raised Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 target price for the company in a research report on Tuesday, June 6th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $176.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, July 4th. Finally, Piper Jaffray Companies set a $182.00 target price on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have given a buy rating to the stock. Jazz Pharmaceuticals PLC has a consensus rating of “Buy” and an average target price of $182.72.

In other Jazz Pharmaceuticals PLC news, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $150.65, for a total transaction of $30,130.00. Following the sale, the executive vice president now owns 22,223 shares in the company, valued at $3,347,894.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Rick E. Winningham sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $150.00, for a total value of $750,000.00. Following the sale, the director now owns 10,391 shares in the company, valued at approximately $1,558,650. The disclosure for this sale can be found here. Insiders have sold 12,566 shares of company stock worth $1,921,138 in the last 90 days. 4.30% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Toronto Dominion Bank boosted its stake in shares of Jazz Pharmaceuticals PLC by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 81 shares during the last quarter. US Bancorp DE boosted its stake in shares of Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 368 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 295 shares during the last quarter. World Asset Management Inc bought a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter worth $205,000. Finally, Gargoyle Investment Advisor L.L.C. bought a new stake in shares of Jazz Pharmaceuticals PLC during the second quarter worth $206,000. Hedge funds and other institutional investors own 87.22% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/20/brokerages-expect-jazz-pharmaceuticals-plc-jazz-to-announce-2-89-eps.html.

Jazz Pharmaceuticals PLC (JAZZ) opened at 144.40 on Friday. The company’s 50-day moving average price is $153.33 and its 200-day moving average price is $147.61. The stock has a market capitalization of $8.67 billion, a PE ratio of 22.24 and a beta of 1.10. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Get a free copy of the Zacks research report on Jazz Pharmaceuticals PLC (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.